Compare ClearPoint Neuro Inc (CLPT) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Roundhill Magnificent Seven ETF — how do they compare? ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M), while Roundhill Magnificent Seven ETF trades at $67.48. The key difference: Roundhill Magnificent Seven ETF is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | MAGS | |
|---|---|---|
Market Cap | $478.63M | — |
Sector | Health | Sector/Thematic |
52-Week High | $29.60 | $70.94 |
52-Week Low | $8.66 | $55.39 |
Enterprise Value | $506.63M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
MAGS, the Roundhill Magnificent Seven ETF, trades at $66.99, down 1.02% on the day. The technical outlook is bullish based on moving averages, while oscillators are neutral. Recent news highlights the ETF's strong performance since launch but notes concentration risk and a recent pullback from 2026 highs. The fund provides equal-weight exposure to mega-cap tech stocks, with assets near $4.7 billion as of May 2026.
The outlook for MAGS hinges on the continued growth and AI monetization of its underlying holdings. Key opportunities include potential free cash flow expansion from hyperscalers, but risks involve high expectations, valuation compression, and the cyclical nature of tech leadership. Market sentiment is mixed, balancing long-term growth prospects against near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
